Physique MD

Learn more

Tirzepatide is the strongest weight-management medication we currently have in large clinical trials — the drug behind the brand names Zepbound (for weight) and Mounjaro (for diabetes). On average it produces more weight loss than the GLP-1 medications that came before it. It is also a serious medication with a real side-effect profile, and the gap between the marketing version and the medical version of this drug is wide. Here is the medical version: what it does, what doses exist, how treatment unfolds over months, what the trials actually showed, and where the caution flags are.

No hype, including about this.

What it is for (indications)

Tirzepatide is a prescription medication for long-term weight management, used together with a reduced-calorie diet and physical activity. The weight-management brand is Zepbound. It is intended for adults with:

  • A body mass index (BMI) of 30 or higher, or
  • A BMI of 27 or higher plus at least one weight-related health condition.

It has two further distinctions worth knowing:

  • Sleep apnea. Tirzepatide was the first medication ever approved (December 2024) to treat moderate-to-severe obstructive sleep apnea in adults with obesity — because losing this much weight measurably opens the airway. The details are in the studies section below.
  • Diabetes. The same drug, sold as Mounjaro, is FDA-approved for type 2 diabetes, and tirzepatide lowers blood sugar more powerfully than any drug in its class. If you have diabetes or prediabetes, that blood-sugar effect is a major part of the decision.

At Physique MD, I also prescribe compounded tirzepatide from licensed 503A pharmacies when that is the appropriate and practical option for a patient. Compounded versions are prepared by the pharmacy for the individual patient; they are not the FDA-approved brand product, and I’ll always tell you plainly which one you’re getting and why. (Physique MD treats adults only, 18 and older.)

Which medication fits your history, your other conditions, and your budget is what your consultation is for — the $50 consultation fee is credited toward treatment if we move forward together.

How it works

Most drugs in this family work on one hormone pathway. Tirzepatide works on two: it activates receptors for both GLP-1 and GIP, two gut hormones involved in appetite and insulin. That dual action is the main reason its average weight-loss numbers run ahead of single-pathway drugs like semaglutide — and it appears to be additive, not just more of the same.

Through those two pathways it:

  • Quiets appetite at the level of the brain — hunger drops, portions shrink, and the constant background “food noise” fades
  • Slows stomach emptying, so meals keep you full longer (this is also the source of most side effects)
  • Improves insulin response — more insulin when blood sugar is high, less glucagon — which is why its blood-sugar numbers in diabetes trials are so strong

Tirzepatide stays in your system with a half-life of about five days, so it is injected once a week, and each dose level takes about four weeks to reach its full, steady effect. It is still a tool, not a bypass: it changes the signals that were fighting you, but protein, movement, and sleep determine how much of the loss is fat versus muscle.

What the studies actually found

  • SURMOUNT-1 (the main weight trial, about 2,540 adults without diabetes, 72 weeks): average weight loss was 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg — versus 3.1% on placebo. At the top dose, about 57 out of 100 people lost 20% or more of their body weight (versus 3 on placebo). For a 230-pound person, 20.9% is roughly 48 pounds. Body-composition scans in a subgroup showed about three-quarters of the weight lost was fat, not lean tissue.
  • SURMOUNT-2 (adults with type 2 diabetes, who typically lose less on every weight drug): about 13–16% average loss depending on dose, versus about 3% on placebo.
  • SURPASS-2 (head-to-head against semaglutide 1 mg in type 2 diabetes): tirzepatide lowered A1C more at every dose — by about 2.0 to 2.3 percentage points, versus 1.9 for semaglutide — with greater weight loss at every dose too (about 8–11 kg versus about 6 kg).
  • SURMOUNT-5 (the direct comparison patients ask about — tirzepatide versus full-dose semaglutide 2.4 mg, 72 weeks): average loss was about 20% with tirzepatide versus about 14% with semaglutide. That is the honest, same-trial answer to “which one is stronger?”
  • SURMOUNT-OSA (sleep apnea, 52 weeks): in people not using a CPAP machine, apnea severity (the AHI score) fell by about 55% on tirzepatide versus 5% on placebo; in people using CPAP, it fell by about 63% versus 6%. Roughly 43–52% of treated patients improved enough to meet the study’s disease-resolution criteria. That is why this drug, alone in its class, carries the sleep-apnea indication.
  • Diabetes prevention signal: in the three-year follow-up of SURMOUNT-1 participants with prediabetes, only 1.2% of those on tirzepatide progressed to type 2 diabetes, versus 12.6% on placebo.

Read these the honest way: they are averages, at studied doses, in trial populations. Individual results vary, some people respond dramatically and a minority respond very little, and no result can be guaranteed to any specific person.

Doses and how to use it

Tirzepatide is a once-a-week injection under the skin of the abdomen, thigh, or outer upper arm, on the same day each week, at any time of day, with or without food. Rotate the exact spot each week. The brand product comes as single-dose prefilled pens and single-dose vials; compounded tirzepatide typically comes as a vial you draw from with a small insulin syringe — the dose steps are the same either way.

Nobody starts at the top. The schedule rises in 2.5 mg steps, no faster than every four weeks:

  • Weeks 1–4: 2.5 mg once a week — a starting dose only. Its job is to let your stomach adjust; the label is explicit that 2.5 mg is not a maintenance dose
  • Week 5 onward: 5 mg once a week
  • Then, if needed and tolerated: 7.5 mg → 10 mg → 12.5 mg → up to the maximum of 15 mg, each step separated by at least four weeks

Reaching the top dose takes a minimum of about five months, and many patients never need it. The labeled maintenance doses for weight management are 5 mg, 10 mg, or 15 mg (for sleep apnea, 10 or 15 mg). The right dose is the lowest one that is doing the job and that you can live with — we increase because progress has stalled or goals aren’t met, not because the schedule says so. If a step causes significant side effects, staying put longer is always an option.

Storage

  • Store in the refrigerator (36–46°F / 2–8°C), in the original carton to protect from light.
  • Never freeze — tirzepatide that has frozen must be thrown away.
  • If needed, a single-dose pen or vial can be kept at room temperature (up to 86°F / 30°C) for up to 21 days — handy for travel — but once it has been at room temperature, do not put it back in the refrigerator, and discard it after 21 days out.
  • Compounded vials: refrigerate, never freeze, and follow the storage and beyond-use date on your pharmacy’s label — they differ from the brand rules.

If you miss a dose

  • If you remember within 4 days (96 hours) of your scheduled day, take the dose, then take your next dose on your usual day.
  • If more than 4 days have passed, skip the missed dose and take the next one on schedule. Never double up.
  • You can move your injection day as long as there are at least 3 days (72 hours) between doses — two doses must never be taken within 3 days of each other.
  • If you have missed several weeks, contact us before restarting. Tolerance fades during a gap, and jumping back to your old dose is a reliable way to spend two days vomiting — we may restart lower and step back up.

Side effects / what to expect

Like the rest of this drug family, tirzepatide’s side effects are dominated by the stomach and bowel, are most common during dose increases, and usually ease with time. From the FDA-approved labeling (pooled weight-management trials; rates shown for the 5 / 10 / 15 mg doses, versus placebo):

  • Nausea — 25 / 29 / 28 out of 100 people (8 on placebo)
  • Diarrhea — 19 / 21 / 23 out of 100 (8 on placebo)
  • Constipation — 17 / 14 / 11 out of 100 (5 on placebo)
  • Vomiting — 8 / 11 / 13 out of 100 (2 on placebo)
  • Stomach pain, indigestion, reflux, belching — each in roughly 4–10 out of 100
  • Injection-site reactions — 6–8 out of 100 (2 on placebo)
  • Fatigue — 5–7 out of 100; dizziness — about 4–5 out of 100
  • Hair shedding — 4–5 out of 100 (1 on placebo) — usually the temporary shedding that follows rapid weight loss itself; see my hair-loss page

In trials using higher doses or certain populations, nausea has been reported in up to about 4 in 10 people. Overall, about 5–7 out of 100 people on tirzepatide stopped the medication because of side effects (versus about 3 on placebo), most often digestive, most often early.

What actually helps, from practice:

  • Eat smaller meals and stop at the first feeling of fullness — overfilling a slowed stomach is the most reliable trigger for nausea and vomiting
  • Keep meals lower in fat during escalation weeks
  • Sip fluids through the day; add electrolytes if you’re losing fluid from either end
  • For constipation: fiber, water, and movement first — ask us before using anything stronger regularly
  • If a dose step is rough, tell us. Slowing the climb is a legitimate strategy, and prescription anti-nausea medication exists for the hard stretches

The serious list, because you deserve the whole picture:

  • Thyroid tumors — the boxed warning. Tirzepatide carries the FDA’s strongest (“boxed”) warning about thyroid C-cell tumors, seen in rat studies. It must not be used if you or a family member has had medullary thyroid carcinoma (MTC), or if you have MEN 2 (multiple endocrine neoplasia syndrome type 2). Whether it causes these tumors in humans is unknown — the warning exists so we screen for the risk factors, not so you panic about it.
  • Pancreatitis (inflammation of the pancreas) has been reported, including rare severe cases. If it is suspected, the drug is stopped — and after a confirmed episode, it is not restarted. Call promptly for severe stomach pain that bores through to the back.
  • Gallbladder problems, including gallstones, occur more often — rapid weight loss itself is part of that story.
  • Severe stomach problems. Because tirzepatide slows stomach emptying, it is not recommended for people with severe gastroparesis, and severe digestive reactions can occur.
  • Kidney injury can follow dehydration from heavy vomiting or diarrhea — pushing fluids and calling early is the prevention.
  • Low blood sugar is mainly a risk when tirzepatide is combined with insulin or sulfonylurea diabetes pills (see below), not when it is used alone.
  • Serious allergic reactions, including rare anaphylaxis and angioedema, have been reported with this drug class — swelling of the face, lips, or tongue, or trouble breathing, is an emergency.

Who should not take it

Tirzepatide is not for you if:

  • You or a family member has had medullary thyroid carcinoma, or you have MEN 2
  • You have had a serious allergic reaction to tirzepatide or any of its ingredients

It needs real caution — and a direct conversation with me — if you have:

  • A history of pancreatitis
  • Severe gastroparesis or other severe stomach/bowel motility problems (the label advises against use)
  • Diabetic eye disease (retinopathy) — rapid blood-sugar improvement can temporarily worsen it
  • Significant kidney problems, gallbladder disease, depression or mood disorders, or a history of an eating disorder

Pregnancy. Tirzepatide may harm a developing baby (based on animal data), and weight loss offers no benefit during pregnancy. The label’s instruction: stop it when pregnancy is recognized, and do not use it while trying to conceive without a plan we have made together. If pregnancy happens on it, stop and contact us. One more wrinkle specific to this drug — it can make birth control pills less reliable at exactly the moments doses change; that is covered in the next section, and it is not optional reading if you use the pill.

Other medicines, alcohol, and surgery

  • Birth control pills — read this one carefully. Tirzepatide’s effect on stomach emptying is strongest right after a dose starts or increases, and it can reduce how much of an oral contraceptive gets absorbed. The FDA label’s instruction: if you use an oral hormonal contraceptive, switch to a non-oral method, or add a barrier method (like condoms), for 4 weeks after starting tirzepatide and for 4 weeks after every dose increase. Since the dose typically rises several times in the first months, many patients find a non-oral method simpler for the escalation phase. Do not discover this rule by accident.
  • Other oral medications. The same slowed stomach can change the absorption of other pills, especially early on and especially medicines where the blood level needs to be exact (thyroid medication is a common example — we monitor levels). Bring a complete list of everything you take, including over-the-counter products, to your consultation.
  • Insulin and sulfonylurea diabetes pills (like glipizide or glyburide): combined with tirzepatide, these can push blood sugar too low. Their doses often need to come down as your glucose improves — never adjust them on your own, but expect adjustments.
  • Alcohol. Not absolutely forbidden, but on a slowed stomach it commonly worsens nausea and reflux, adds empty calories, and can contribute to low blood sugar if you take diabetes medication. Heavy drinking also raises pancreatitis risk. Most patients find they naturally want less.
  • Surgery and procedures. The labeling warns that food can remain in the stomach longer than expected even after normal fasting, raising a small risk of food entering the lungs during anesthesia. Tell every surgeon, dentist, and anesthesiologist that you take tirzepatide. For elective procedures, teams commonly ask patients to skip the weekly dose in the week before — follow their instructions, and tell us too.

What to expect, month by month

  • Month 1 (2.5 mg): the adjustment dose. Appetite may dip slightly; mild nausea is possible; expect little weight change. This month is the runway.
  • Months 2–3 (5 mg, then 7.5 mg if we climb): appetite suppression becomes unmistakable — smaller portions, less snacking, quieter “food noise.” Steady loss begins, commonly around 1–2 pounds a week.
  • Months 4–6 (7.5–12.5 mg as needed): the strongest stretch of loss for most people, and when side effects tend to peak around each step up. Protein at every meal and resistance exercise protect your muscle now, while the loss is fast.
  • Months 6–12+: loss continues but gradually slows, typically leveling off somewhere around or after the one-year mark in the trials. Sleep apnea, blood pressure, and blood sugar improvements often show up in this window too.

About plateaus. They are expected, not a verdict. A smaller body burns fewer calories than a larger one did (arithmetic, not a broken metabolism), appetite suppression softens somewhat with time, and habits quietly loosen. The dose may still have room to rise — that is one advantage of the six-step ladder — but a plateau is a conversation about dose, labs, sleep, and other medications, not an instruction to eat nothing.

Maintenance. The labeled maintenance doses are 5, 10, or 15 mg weekly. Most patients who reach their goal stay on a maintenance dose rather than stopping — for the reason in the next section.

What happens if you stop

The trials have tested exactly this, and you should know the result before you start:

  • In SURMOUNT-4, everyone took tirzepatide for 36 weeks first (average loss about 21%). Half then continued the drug; half were switched to placebo without being told. Over the next year, the switched group regained about 14% of body weight, while the group that stayed on it lost a further 5.5%. About 9 in 10 of those who continued kept at least 80% of their loss — versus only about 1 in 6 of those who stopped.

That is not a character flaw in the patients who regained; it is the biology of a chronic, relapsing condition reasserting itself when treatment is removed — the same reason blood pressure rises when blood-pressure medicine is stopped. Stopping can still be the right choice for some patients, with a deliberate maintenance plan. But the honest starting assumption is that this is long-term treatment.

Questions patients ask me

“Is this stronger than Ozempic/Wegovy? Should I just start with the strongest?”
On average, yes — the head-to-head trial showed about 20% average loss on tirzepatide versus about 14% on semaglutide at full doses. But “strongest average” is not the same as “right for you.” Diabetes, sleep apnea, side-effect sensitivity, other medications, and cost all enter the decision, and some patients do beautifully on semaglutide. That comparison is what your consultation is for.

“Why does the dose go up so slowly? Can’t we skip to 15 mg?”
No — and this is a safety rule, not red tape. The stomach effects are dose-related, and the four-week steps are how the body adapts. People who jump doses are the people who end up in urgent care with vomiting. The slow climb is also how we find your lowest effective dose; many patients never need the top.

“I’m on the birth control pill. What do I actually need to do?”
For 4 weeks after your first dose, and again for 4 weeks after every dose increase, either switch to a non-oral method or add condoms. Because increases happen repeatedly in the first several months, most patients on the pill choose a non-oral method for that whole phase. If this paragraph is the first you’re hearing of it, call us before your next dose, not after.

“Will I lose muscle?”
Some lean mass is lost with any large weight loss — in SURMOUNT-1’s body-composition data, roughly three-quarters of the loss was fat and one-quarter lean tissue, which is a typical-to-favorable ratio. You can shift it further in your favor: adequate protein every day and resistance exercise are the two levers, and I will nag you about both.

“My hair is shedding. Is the drug damaging it?”
Almost always this is telogen effluvium — the temporary shedding that follows rapid weight loss of any kind — reported by about 4–5 out of 100 people on tirzepatide in trials. It typically starts a few months into fast loss and regrows. Keeping protein and iron adequate helps; if shedding is heavy or patchy, tell me, because other causes deserve a look. My hair-loss page covers this in depth.

“Will I have to take this forever?”
Plan on long-term. The withdrawal trial above is the reason: stopping usually means regaining most of the weight within a year or so. Some patients taper off successfully with a serious maintenance plan, but “long-term, like blood-pressure medicine” is the honest starting assumption.

When to call us

Call or message promptly if you have:

  • Repeated vomiting or diarrhea, or you can’t keep fluids down
  • Severe or persistent stomach pain — especially pain that bores through to your back (possible pancreatitis), or pain under the right ribs (possible gallbladder)
  • Signs of an allergic reaction: rash, itching, swelling of the face/lips/tongue, trouble breathing
  • Symptoms of very low blood sugar if you also take diabetes medication (shakiness, sweating, confusion, racing heart)
  • Noticeably worse mood or new depression
  • A positive pregnancy test

References

  • Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205–216.
  • Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). The Lancet. 2023;402:613–626.
  • Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021;385:503–515.
  • Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine. 2024;391:1193–1205.
  • Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48.
  • Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. 2025.
  • Jastreboff AM, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention — three-year SURMOUNT-1 results. New England Journal of Medicine. 2025.
  • Zepbound (tirzepatide) injection — U.S. Prescribing Information. Eli Lilly. (Dose schedule, maintenance doses, adverse-reaction rates, storage, missed doses, and the oral-contraceptive and boxed warnings.)
  • American Diabetes Association. Standards of Care in Diabetes — 2025: Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes.
  • American Gastroenterological Association (AGA) Clinical Practice Guideline on Pharmacological Interventions for Adults with Obesity. Gastroenterology. 2022.

Educational only — not medical advice.

Medically reviewed by Leena Almarzouqi, MD, MPH